Astellas Pharma acquires Ogeda SA for €800 million (US$852 million)
Jones Day is advising Astellas Pharma Inc., a Japanese leader in the pharma industry, in its €800 million (US$852 million) acquisition of Ogeda SA, a privately owned Belgian drug discovery company.
In addition to M&A representation, Jones Day is providing antitrust and intellectual property advice regarding this transaction.
For additional information about this matter, please contact: Thomas De Muynck
Client(s): Astellas Pharma Inc.
Practice(s): M&A, Antitrust & Competition Law, Intellectual Property, Tax